Based upon the similarity of global proteomic data in bulk and cored samples and the distinct proteomic profiles in LMD samples (Fig. 2), we further evaluated the enrichment of neoplastic cellularity using the percent of variant allelic frequency (VAF) of KRAS mutations derived from WES as a surrogate signature for neoplastic cellularity for tumor tissues prepared by bulk, coring, or LMD. The gene discussed is KRAS; the disease is neoplasm.